Mayo Clinic School of Continuous Professional Development 13400 East Shea Boulevard Scottsdale, Arizona 85259 Telephone: (480) 301-4580 Dear Representative, On behalf of Mayo Clinic and Mayo Clinic School of Continuous Professional Development, we are pleased to announce our new continuing medical education activity Mayo Clinic Gastrointestinal Cancers 2018: Current and Emerging Strategies in Multidisciplinary Care: Translating Evidence into Best Practices that will be held March 1-3, 2018 at the Hyatt Regency La Jolla at Aventine in San Diego, California. We invite you and your company to exhibit at this CME activity. The exhibit fee is $3,500. Space is limited; early registration is advised. This course will focus on case-based and didactic presentations from Mayo Clinic and other international experts in the treatment of the whole spectrum of gastrointestinal (GI) cancers including esophageal, gastric, hepatocellular, pancreatic, small bowel, bile duct, anal and colorectal and gallbladder. The primary goal of this course is to guide practicing physicians on integrating the best and most current evidence into their day-to-day routine care for patients with GI cancers. This course will also bring a practical perspective on how to optimize multidisciplinary care for some of the more complex clinical management decisions in GI oncology including but not limited to: locoregional modalities, the role of minimally invasive procedures and state-of-the-art radiation modalities. As you can see from the attached program, we have designed an excellent course to give Medical Oncologists, Radiation Oncologists, Surgical Oncologists, GI Surgeons, Gastroenterologists and Hepatologists involved in cancer care, Interventional Radiologists, Pharmacists, Nurse Practitioners, Physician Assistants, Nurses, and any healthcare professional involved in the care of GI malignancies clinically important information in gastrointestinal cancer. NEW Mayo Clinic now offers a variety of sponsorship opportunities for industry support! Please refer to the attached sponsorship description page for available opportunities. If you will join us, please complete the attached exhibitor agreement and return it with your payment (made payable to Mayo Clinic in Arizona) to Mayo Clinic School of Continuous Professional Development, Attn: Kristy Badder, 13400 East Shea Boulevard, Scottsdale, AZ 85259. Please denote course activity #18S05250 on all correspondence. Mayo Clinic s Tax ID number is 86-0800150; our W-9 form is attached for your convenience. To maintain a clear separation of promotion from education, exhibits will be located adjacent to where the educational sessions will be held. Displays should be staffed during breakfasts, breaks, and lunches March 1-3, times are denoted on the attached program. We hope you will join us in San Diego in March! Sincerely, Tanios S. Bekaii-Saab, M.D. Course Director Senior Associate Consultant, Hematology and Oncology Professor of Medicine Mayo Clinic College of Medicine Axel Grothey, M.D. Course Director Consultant, Medical Oncology Professor of Medicine Mayo Clinic College of Medicine
Mayo Clinic School of Continuous Professional Development (MCSCPD) Sponsorship Opportunities Opportunity Cost Lanyards $2,000 (Sponsor-provided, pre-printed lanyards; limited to one organization) Every attendee is required to wear a name badge, so what better way to advertise your company than with your logo on a lanyard! (Quantity to be determined 60 days before course.) Drawstring Bags $3,000 (Sponsor-provided, pre-printed drawstring bags; limited to one organization) Help keep course attendees organized by providing them with a drawstring bag to carry their course materials in with your company s logo on it! Drawstring bags to be provided by sponsor; artwork and bag are subject to MCSCPD approval. (Quantity to be determined 60 days before course.) Hotel Key Cards $4,000 (Limited to one organization) Personalize hotel guest room keys with your company s logo or product promotion for immediate exposure to attendees. Use this as a great way to introduce yourselves to our attendees upon checking into the host hotel. Artwork to be provided by sponsoring company and is subject to MCSCPD approval. (Artwork is due to MCSCPD 90 days before course.) Conference Bag Inserts $1,500 each (Multiple opportunities available) Conference bag inserts are a great opportunity to invite attendees to your booth, announce your booth participation or conference- related event. Your company will provide copies of the flyer or advertisement (no larger than 8 ½ x 11, no more than one page) and the MCSCPD will stuff them into the official conference bags. A limited number of bag inserts are permitted, so early reservation is encouraged. Artwork is subject to MCSCPD approval. (Quantity of fliers/advertisements to be determined 60 days before course.) As an industry supporter, if you have a sponsorship opportunity idea that isn t mentioned on this page, please contact MCSCPD to discuss. If you are interested in one of our sponsorship opportunities contact MCSCPD for more information at mca.cme@mayo.edu or 480-301-4580.
Page 1 of 2 Mayo Clinic School of Continuous Professional Development (MCSCPD) Exhibitor Agreement Activity Title Mayo Clinic Gastrointestinal Cancers 2018 Activity Number 18S05250 Location Hyatt Regency La Jolla at Aventine, San Diego, California Exhibit Dates March 1-3, 2018 Agreement between: ACCREDITED PROVIDER: Mayo Clinic College of Medicine and Science MCSCPD AND: Company Name (Exhibitor) (as it should appear on printed materials) Exhibit Contact (if different then exhibit Rep.) Name(s) of Representative(s) Exhibiting (Maximum of two representatives allowed per exhibit) Address Telephone Fax Email The named exhibitor wishes to exhibit at the above named activity for the amount of $3,500 Sponsorship Opportunities Lanyards (limited to one organizations) $2,000 Drawstring Bags (limited to one organization) $3,000 Hotel Key Cards (limited to one organization) $4,000 Conference Bag Inserts (multiple opportunities available) $1,500 TOTAL AMOUNT $ NOTE: There may be additional charges depending on the meeting location (power, internet access, etc.). Please list additional requests here: (please note: additional requests may incur additional fees) TERMS AND CONDITIONS EXHIBITOR agrees to abide by ACCME Standards for Commercial Support as stated at www.accme.org: SCS 4.2: Product-promotion material or product-specific advertisement of any type is prohibited in or during CME activities. The juxtaposition of editorial and advertising material on the same products or subjects must be avoided. Live (staffed exhibits, presentations) or enduring (printed or electronic advertisements) promotional activities must be kept separate from CME. For live, face-to-face CME, advertisements and promotional materials cannot be displayed or distributed in the educational space immediately before, during or after a CME activity. Providers cannot allow representatives of Commercial Interests to engage in sales or promotional activities while in the space or place of the CME activity. EXHIBITOR may only distribute educational promotional materials at their exhibit space. Distribution of non-educational items (pens, notepads, etc.), pharmaceuticals or product samples is prohibited. All exhibit fees associated with this activity will be given with the full knowledge of the PROVIDER. No additional payments, goods, services or events will be provided to the course director(s), planning committee members, faculty, joint provider, or any other party involved with the activity.
Page 2 of 2 Completion of this agreement represents a commitment and payment is due and collectible by the ACTIVITY DATE unless otherwise agreed upon by the PROVIDER. PROVIDER reserves the right to refuse exhibit space to EXHIBITOR in the event of nonpayment or Code of Conduct violation. PROVIDER agrees to provide exhibit space and may acknowledge EXHIBITOR in activity announcements. PROVIDER reserves the right to assign exhibit space or relocate exhibits at its discretion. By signing below, I agree to the Terms and Conditions outlined on Page 1 of this Exhibitor Agreement (including ACCME Standards for Commercial Support): The person signing below is authorized to enter into this agreement: Exhibitor Representative Name Signature Date Mayo Clinic Representative Name Signature Date Kristy Badder PAYMENT INFORMATION Please indicate your method of payment: PROVIDER Federal Tax ID number is 86-0800150. Please remit check payable to: Mayo Clinic Arizona. Please identify name of course on the check stub. Check Make payable to Mayo Clinic Arizona and remit to: Mayo Clinic School of Continuous Professional Development Attn: Kristy Badder 13400 East Shea Blvd. Scottsdale, AZ 85259 Credit Card or Wire Transfer For payment by credit card or wire transfer, please call the MCSCPD Registrar at 480-301-4580 Do not send credit card information via email or fax. Please identify course 18S05250 on the check. Complete and return this form along with your payment made to Mayo Clinic Arizona, Federal Tax ID# 86-0800150 to: Mayo Clinic School of Continuous Professional Development Attn: Kristy Badder 13400 East Shea Blvd. Scottsdale, AZ 85259 T: 480-301-4580 F: 480-301-9161
Mayo Clinic Gastrointestinal Cancers 2018 Current and Emerging Strategies in Multidisciplinary Care: Translating Evidence into Best Practices March 1-3, 2018 Thursday, March 1, 2018 Program Schedule 12:00 p.m. Registration and Refreshments 12:45 Welcome Announcements INTERACTIVE CASE PRESENTATIONS Moderator: Robert R. McWilliams, M.D. 1:00 Advanced Non-Metastatic Pancreas Cancer: How to Maximize Chances of Successful Resection? Case Presenter: Mark J. Truty, M.D., M.S. Panel: Michael L. Kendrick, M.D., Robert R. McWilliams, M.D., Ramesh K. Ramanathan, M.D., Terence T. Sio, M.D., M.S., Mark J. Truty, M.D., M.S. 1:55 Early Stage Rectal Cancer 2:50 Break Discussion 1: Do Shorter Total Neo-Adjuvant Courses Make More Sense? Case Presenter: Nitin Mishra, M.D. Panel: David A. Etzioni, M.D., Chris L. Hallemeier, M.D., Joleen M. Hubbard, M.D., Pashtoon M. Kasi, M.D., Amit Merchea, M.D., Nitin Mishra, M.D. Discussion 2: Is There a Role for Non-Operative Management? Case Presenter: Chris L. Hallemeier, M.D. Panel: David A. Etzioni, M.D., Chris L. Hallemeier, M.D., Joleen M. Hubbard, M.D., Pashtoon M. Kasi, M.D., Amit Merchea, M.D., Nitin Mishra, M.D. 3:10 Early Stage Gastro-Esophageal Cancer: How to Optimize Neoadjuvant Therapy to Maximize Benefit? Case Presenter: Harry H. Yoon, M.D. Panel: Daniel H. Ahn, D.O., Jonathan B. Ashman, M.D., Ph.D., Dennis Wigle, M.D., Ph.D., Harry H. Yoon, M.D. 4:05 Locally Advanced Hepatocellular Carcinoma: Local vs. Systemic Therapy Case Presenter: Mitesh J. Borad, M.D. Panel: Mitesh J. Borad, M.D., Amit Mahipal, M.B.B.S., Kabir Mody, M.D., Rahmi Oklu, M.D., Ph.D., Beau Toskich, M.D. 5:00 Closing Remarks 5:05 Adjourn Page 1
Friday, March 2, 2018 7:00 a.m. Continental Breakfast 7:50 Announcements SESSION I: EMERGING TREATMENT STRATEGIES IN GASTRO-ESOPHAGEAL CANCER Moderator: Jonathan B. Ashman, M.D., Ph.D. 8:00 Integrating PET Scans in the Decision-Making for GE Cancer Treatment Michael C. Roarke, M.D. 8:20 Immunotherapeutic Strategies in GE Cancer: Who is a Candidate? Harry H. Yoon, M.D. 8:40 Anti-Angiogenic Agents in GE Cancer: Where Do They Fit in the Therapeutic Landscape? Daniel Ahn, D.O. 9:00 Minimally Invasive Surgical Interventions in Early-Stage GE Cancer Dennis Wigle, M.D., Ph.D. 9:20 Break SESSION II: EMERGING STRATEGIES TO OPTIMIZE OUTCOME IN METASTATIC COLORECTAL CANCER (mcrc) Moderator: Axel Grothey, M.D. 9:40 From Anatomical location to CMS classification: Implications on Treatment Approach Heinz-Josef Lenz, M.D., FACP 10:00 The Emerging Role of Liquid Biopsies in the Treatment Landscape of mcrc John Strickler, M.D. 10:20 BRAF and RAS Mutations in mcrc : How I Treat? Scott Kopetz, M.D., Ph.D., FACP 10:40 Immunotherapeutic Strategies in CRC: Beyond MSI-high and Advanced Settings? Frank A. Sinicrope, M.D. 11:00 Predictors of Outcome with Regorafenib and TAS102 Pashtoon M. Kasi, M.D. 11:40 Lunch Page 2
Friday, March 2, 2018 (continued) SESSION III: OPTIMIZING OUTCOME IN EARLY STAGE AND OLIGO-METASTATIC COLORECTAL CANCER Moderator: Nitin Mishra, M.D. 12:30 p.m. Radioembolization in Liver-only or Liver-dominant mcrc: Is there a Fit? Steven R. Alberts, M.D. 12:50 Liver Resection in mcrc: Who is an Optimal Candidate? Chee-Chee H. Stucky, M.D. 1:10 Survivorship in the Long-term Care of Patients with CRC David A. Etzioni, M.D. 1:30 Optimal Duration in the Adjuvant Treatment of CRC: Do We Have an IDEA? Axel Grothey, M.D. 1:50 Debate: Role of HIPEC in the Management of CRC with Peritoneal only Disease HIPEC Rules! Nabil Wasif, M.D. Time to Move Beyond HIPEC! Amit Merchea, M.D. Panel Discussion Nabil Wasif, M.D. and Amit Merchea, M.D. 2:30 Break SESSION IV: INTERPRETATION OF CLINICAL TRIALS AND LARGE DATABASES IN GI CANCERS Moderator: Qian Shi, Ph.D. 2:50 Clinical Trial Conduct and Monitoring Fang-Shu Ou, Ph.D. 3:10 Working with Large Databases (ACCENT, ARCAD, and IDEA): The Past as Prologue Qian Shi, Ph.D. 3:30 Closing Remarks 3:35 Adjourn Page 3
Saturday, March 3, 2018 7:00 a.m. Continental Breakfast 7:50 Announcements SESSION V: EMERGING TREATMENT STRATEGIES IN PANCREAS CANCER Moderator: Ramesh K. Ramanathan, M.D. 8:00 Optimizing Sequencing in the Treatment of Metastatic Pancreas Cancer Wen Wee Ma, M.B.B.S. 8:20 Emerging Strategies in the Treatment of Metastatic Pancreas Cancer Ignacio Garrido-Laguna, M.D., Ph.D. 8:40 Total Neoadjuvant Treatment for Resectable Pancreas Cancer: Is it Time? Mark J. Truty, M.D., M.S. 9:00 Minimally Invasive Surgical Interventions in Pancreas Cancer Michael L. Kendrick, M.D. 9:20 Break SESSION VI: EMERGING STRATEGIES TO OPTIMIZE OUTCOME IN HEPATOBILIARY CANCERS Moderator: Daniel Ahn, D.O. 9:40 Tyrosine Kinase Inhibitors Galore: What is the Optimal Sequence? Mitesh J. Borad, M.D. 10:00 Immunotherapeutic Strategies in HCC: A Shifting Landscape Anthony B. El-Khoueiry, M.D. 10:20 The Expanding Role of Proton Therapy in Localized Hepatobiliary Cancers Jonathan B. Ashman, M.D., Ph.D. 10:40 When to Refer Your Patient with Hepatobiliary Cancer for Consideration of Transplant? Adyr A. Moss, M.D. 11:00 Genetic Diversity in Biliary Cancer Milind Javle, M.D. 11:20 Debate: Role of Adjuvant Therapy in Biliary Cancer Chemotherapy is the Standard Bassel F. El-Rayes, M.D. Observation is the Standard Kabir Mody, M.D. Panel Discussion Bassel F. El-Rayes, M.D. and Kabir Mody, M.D. 12:00 p.m. Lunch Page 4
Saturday, March 3, 2018 (continued) SESSION VII: NEUROENDOCRINE CANCER Moderator: Amit Mahipal, M.D. 12:50 Surgical (including Liver Transplant) Options in Metastatic NET to the Liver: Who is a Candidate? Amit K. Mathur, M.D. 1:10 Systemic Therapies in NET Thorvardur R. Halfdanarson, M.D. 1:30 Emerging Strategies in the Treatment Landscape of NET Jonathan R. Strosberg, M.D. SPECIAL LECTURES Moderator: Tanios S. Bekaii-Saab, M.D. 1:50 Her2 as a Target in GI Malignancies John H. Strickler, M.D. 2:05 Biosimilars Are Not Biosames: So What? Tanios S. Bekaii-Saab, M.D. 2:30 Closing Remarks 2:35 Adjourn Page 5